Actively Recruiting
Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
Led by Weill Cornell Medical College in Qatar · Updated on 2026-04-29
90
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
W
Weill Cornell Medical College in Qatar
Lead Sponsor
H
Hamad Medical Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating how endothelial progenitor cells (EPCs), which help repair blood vessels, behave in people with type 2 diabetes (T2D) and cardiovascular complications. The study focuses on understanding how EPC dysfunction, influenced by abnormal cell signaling and chronic inflammation, contributes to the progression of atherosclerosis in T2D. A special sub-study will explore ways to improve EPC function by enhancing the activity of a key protein called endothelial nitric oxide synthase (eNOS). Participants will have EPCs isolated from their blood for detailed analysis. The study includes groups of people with T2D without cardiovascular complications, those with T2D and coronary artery disease, and a control group without T2D. The sub-study will test whether increasing eNOS activity in EPCs can improve their ability to repair blood vessels. Various laboratory tests will measure gene expression, calcium signaling, inflammation markers, and EPC function both before and after gene enhancement. During the study, participants will provide blood and urine samples for EPC isolation and testing. Researchers will assess EPC dysfunction, inflammatory responses, and their capacity to mature into vascular cells over a period of 15 to 20 days. The sub-study will evaluate the effects of genetic enhancement on EPC function 72 hours after gene transfection. This comprehensive evaluation aims to better understand vascular complications in T2D and explore potential therapeutic strategies.
CONDITIONS
Brief Title
Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of type 2 diabetes
- Male or female participants
- Age 18 years or older
- Willing to participate and provide written consent
- Consent to blood and urine sample collection for study purposes
You will not qualify if you...
- Does not meet inclusion criteria
- Diagnosis of type 1 diabetes, MODY diabetes, or other diabetes types
- Active infection, inflammation, cancer, or acute illness (except cardiovascular complications of diabetes)
- Chronic inflammatory or infectious diseases such as autoimmune disorders, HIV, or chronic hepatitis
- History of cancer within the past 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 15 to 20 days
Participants provide blood and urine samples to assess endothelial progenitor cell function and inflammatory responses related to type 2 diabetes and cardiovascular complications.
1 visit for sample collection
Duration - Up to approximately 34 days including in vitro assessments
Participants are observed for EPC characteristics and function, including responses to potential therapeutic strategies in vitro.
No in-person visits; laboratory assessments performed on collected samples
Trial Site Locations
Total: 1 location
1
Hamad Medical Corporation
Doha, Qatar
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here